Objective To estimate the coronavirus disease 2019 (COVID-19) vaccine effectiveness (VE)
against concerned outcomes in real-world settings. Methods Studies reporting COVID-19 VE …

The past several months have witnessed the emergence of SARS-CoV-2 variants with novel
spike protein mutations that are influencing the epidemiological and clinical aspects of the …

Introduction The inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) has
been widely used in a two-dose schedule. We assessed whether a third dose of the …

Adjuvants are indispensable components of vaccines. Despite being widely used in
vaccines, their action mechanisms are not yet clear. With a greater understanding of the …

Background Large-scale vaccination against COVID-19 is being implemented in many
countries with CoronaVac, an inactivated vaccine. We aimed to assess the immune …

Background It was urgent and necessary to synthesize the evidence for vaccine
effectiveness (VE) against SARS-CoV-2 variants of concern (VOC). We conducted a …

Global case and death incidences continued to decrease with over 3 million new weekly
cases and over 73 000 new deaths, a 15% and an 8% decrease respectively, compared to …

Background All currently available SARS-CoV-2 vaccines are administered by intramuscular
injection. We aimed to evaluate the safety and immunogenicity of a live-attenuated influenza …

There is considerable interest in the waning of effectiveness of coronavirus disease 2019
(COVID-19) vaccines and vaccine effectiveness (VE) of booster doses. Using linked national …

Since December 2019, over 1.5 million SARS-CoV-2-related fatalities have been recorded
in the World Health Organization European Region-90.2% in people≥ 60 years. We …